REHOVOT, Israel and HOBOKEN, N.J., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field, today announced that its Board of Directors has declared a cash dividend of $0.17 (approximately NIS 0.50) per share on the Company’s ordinary shares (totaling approximately $9.8 million). The cash dividend will be payable on September 17, 2026, to shareholders of record at the close of business on August 27, 2026. The dividend payment is consistent with the Company’s dividend policy.
Read more at globenewswire.com
